Boundless Bio Inc

For the period ended Mar 31, 2025. Filed May 9, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 9, 2025

BOLD$2.46+2.1%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Balance Sheets

(in thousands, except par value data)

	March 31,	December 31,
	2025	2024
(unaudited)
Assets
Current assets
Cash and cash equivalents	$15,117	$26,587
Short-term investments	123,136	125,527
Prepaid expenses and other current assets	2,111	2,276
Total current assets	140,364	154,390
Property and equipment, net	4,085	4,321
Right-of-use asset, net	46,183	47,039
Restricted cash	560	560
Other assets	50	99
Total assets	$191,242	$206,409
Liabilities and stockholders’ equity
Current liabilities
Accounts payable and accrued liabilities	$4,953	$5,354
Accrued compensation	1,123	2,781
Lease liabilities, current portion	262	—
Total current liabilities	6,338	8,135
Lease liabilities, non-current	48,312	47,632
Total liabilities	54,650	55,767
Commitments and contingencies (Note 8)
Stockholders’ equity
Preferred stock, $0.0001 par value; 70,000 shares authorized and no shares issued and outstanding as of March 31, 2025 and December 31, 2024	—	—
Common stock, $0.0001 par value; 700,000 shares authorized, 22,300 shares issued and outstanding as of March 31, 2025 and December 31, 2024	2	2
Additional paid-in-capital	353,788	351,991
Accumulated other comprehensive income	32	121
Accumulated deficit	(217,230)	(201,472)
Total stockholders’ equity	136,592	150,642
Total liabilities and stockholders’ equity	$191,242	$206,409

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.